In the clinical setting, the pan-isoform PI3K inhibitor SAR245408 (XL147) [64] and the pan-isoform PI3K and mTOR inhibitor SAR245409 (XL765) [15] have been evaluated in patients with lymphoma, as an expansion cohort of the respective phase I clinical trials. Here, PIK3CB is linked to lymphoma.